KR102736073B1 - Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법 - Google Patents
Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법 Download PDFInfo
- Publication number
- KR102736073B1 KR102736073B1 KR1020207030741A KR20207030741A KR102736073B1 KR 102736073 B1 KR102736073 B1 KR 102736073B1 KR 1020207030741 A KR1020207030741 A KR 1020207030741A KR 20207030741 A KR20207030741 A KR 20207030741A KR 102736073 B1 KR102736073 B1 KR 102736073B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- carcinoma
- cancer
- pyrimidin
- equiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081328 | 2018-03-30 | ||
| CNPCT/CN2018/081328 | 2018-03-30 | ||
| PCT/US2019/024645 WO2019191470A1 (en) | 2018-03-30 | 2019-03-28 | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200138769A KR20200138769A (ko) | 2020-12-10 |
| KR102736073B1 true KR102736073B1 (ko) | 2024-12-02 |
Family
ID=67439309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207030741A Active KR102736073B1 (ko) | 2018-03-30 | 2019-03-28 | Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11524960B2 (enExample) |
| EP (1) | EP3774805B1 (enExample) |
| JP (2) | JP7350005B2 (enExample) |
| KR (1) | KR102736073B1 (enExample) |
| CN (1) | CN111936499B (enExample) |
| AR (1) | AR115326A1 (enExample) |
| AU (1) | AU2019243289B2 (enExample) |
| BR (1) | BR112020020104A2 (enExample) |
| CA (1) | CA3094476C (enExample) |
| EA (1) | EA202092320A1 (enExample) |
| ES (1) | ES2973114T3 (enExample) |
| HU (1) | HUE066282T2 (enExample) |
| IL (1) | IL277665B2 (enExample) |
| MA (1) | MA52232A (enExample) |
| MX (1) | MX2020010005A (enExample) |
| PH (1) | PH12020551507A1 (enExample) |
| PL (1) | PL3774805T3 (enExample) |
| SG (1) | SG11202009195WA (enExample) |
| TW (1) | TWI719437B (enExample) |
| UA (1) | UA127059C2 (enExample) |
| WO (1) | WO2019191470A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503467B2 (en) | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| US12077534B2 (en) * | 2018-12-27 | 2024-09-03 | Les Laboratoires Servier | Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| AU2019414446A1 (en) * | 2018-12-27 | 2021-07-15 | Les Laboratoires Servier Sas | Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| AR119046A1 (es) * | 2019-05-31 | 2021-11-17 | Agios Pharmaceuticals Inc | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer |
| WO2021252680A1 (en) * | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US20240208965A1 (en) * | 2020-06-10 | 2024-06-27 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| EP4165040B1 (en) * | 2020-06-10 | 2025-08-27 | Ideaya Biosciences, Inc. | 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| US20230227409A1 (en) * | 2020-06-10 | 2023-07-20 | Ideaya Biosciences, Inc. | Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| CN115960098B (zh) * | 2020-09-11 | 2026-04-10 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| TW202214630A (zh) * | 2020-09-12 | 2022-04-16 | 大陸商成都倍特藥業股份有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用 |
| CN115960099A (zh) * | 2020-09-24 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| CN114507231B (zh) * | 2020-11-17 | 2025-06-03 | 南京再明医药有限公司 | 内酰胺类化合物及其制备方法 |
| CN114634521A (zh) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| WO2022143864A1 (zh) | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022222911A1 (zh) * | 2021-04-19 | 2022-10-27 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
| JP7721686B2 (ja) * | 2021-06-02 | 2025-08-12 | 南京正大天晴制薬有限公司 | メチオニンアデノシルトランスフェラーゼ２ａ阻害剤 |
| CN118434722A (zh) | 2021-10-20 | 2024-08-02 | 英矽智能科技知识产权有限公司 | 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途 |
| CN118265700A (zh) * | 2021-11-09 | 2024-06-28 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| CN114028572B (zh) * | 2021-11-30 | 2022-11-25 | 清华大学 | Mat2a抑制剂用于治疗哮喘的新应用 |
| CN118414338A (zh) * | 2021-12-21 | 2024-07-30 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| WO2023125737A1 (en) * | 2021-12-29 | 2023-07-06 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds and use thereof |
| KR20240138099A (ko) * | 2022-01-26 | 2024-09-20 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제 |
| CN118742550B (zh) * | 2022-03-11 | 2025-09-05 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| AU2023299635A1 (en) | 2022-06-27 | 2025-01-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Tricyclic compounds and uses thereof |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| EP4582423A1 (en) | 2022-10-13 | 2025-07-09 | Hanmi Pharm. Co., Ltd. | Novel tricyclic derivative compound and uses thereof |
| CN121241050A (zh) * | 2023-03-06 | 2025-12-30 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| EP4729518A1 (en) * | 2023-06-14 | 2026-04-22 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Crystal form of methionine adenosyltransferase 2a heterocyclic inhibitor, preparation method therefor, and use thereof |
| WO2025000265A1 (en) * | 2023-06-28 | 2025-01-02 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds usefull as sos1 inhibitor |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025088571A1 (en) * | 2023-10-26 | 2025-05-01 | Astrazeneca Ab | Crystalline forms of tead inhibitor |
| CN117567473B (zh) * | 2023-11-09 | 2025-07-04 | 中国药科大学 | 一种靶向同源二聚体的抑制剂及其制备方法与应用 |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016064960A1 (en) * | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4429799A (en) | 1998-06-12 | 1999-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| JP5993742B2 (ja) | 2009-10-29 | 2016-09-14 | ジェノスコ | キナーゼ阻害剤 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2017291812B2 (en) | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| UA125852C2 (uk) | 2016-08-31 | 2022-06-22 | Ле Лаборатуар Сервьє | Інгібітори клітинних метаболічних процесів |
| WO2018039972A1 (en) | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
-
2019
- 2019-03-28 HU HUE19744896A patent/HUE066282T2/hu unknown
- 2019-03-28 EP EP19744896.2A patent/EP3774805B1/en active Active
- 2019-03-28 JP JP2020552849A patent/JP7350005B2/ja active Active
- 2019-03-28 MA MA052232A patent/MA52232A/fr unknown
- 2019-03-28 UA UAA202006905A patent/UA127059C2/uk unknown
- 2019-03-28 KR KR1020207030741A patent/KR102736073B1/ko active Active
- 2019-03-28 US US17/040,614 patent/US11524960B2/en active Active
- 2019-03-28 CA CA3094476A patent/CA3094476C/en active Active
- 2019-03-28 AU AU2019243289A patent/AU2019243289B2/en active Active
- 2019-03-28 PL PL19744896.2T patent/PL3774805T3/pl unknown
- 2019-03-28 WO PCT/US2019/024645 patent/WO2019191470A1/en not_active Ceased
- 2019-03-28 CN CN201980023557.8A patent/CN111936499B/zh active Active
- 2019-03-28 MX MX2020010005A patent/MX2020010005A/es unknown
- 2019-03-28 EA EA202092320A patent/EA202092320A1/ru unknown
- 2019-03-28 BR BR112020020104-9A patent/BR112020020104A2/pt active Search and Examination
- 2019-03-28 SG SG11202009195WA patent/SG11202009195WA/en unknown
- 2019-03-28 ES ES19744896T patent/ES2973114T3/es active Active
- 2019-03-29 TW TW108111265A patent/TWI719437B/zh active
- 2019-03-29 AR ARP190100845A patent/AR115326A1/es active IP Right Grant
-
2020
- 2020-09-18 PH PH12020551507A patent/PH12020551507A1/en unknown
- 2020-09-29 IL IL277665A patent/IL277665B2/en unknown
-
2023
- 2023-06-01 JP JP2023090963A patent/JP2023101762A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016064960A1 (en) * | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7350005B2 (ja) | 2023-09-25 |
| KR20200138769A (ko) | 2020-12-10 |
| PL3774805T3 (pl) | 2024-05-06 |
| HUE066282T2 (hu) | 2024-07-28 |
| AU2019243289A1 (en) | 2020-09-24 |
| WO2019191470A1 (en) | 2019-10-03 |
| IL277665A (en) | 2020-11-30 |
| JP2023101762A (ja) | 2023-07-21 |
| JP2021519783A (ja) | 2021-08-12 |
| PH12020551507A1 (en) | 2021-09-13 |
| TW201946629A (zh) | 2019-12-16 |
| IL277665B2 (en) | 2023-06-01 |
| MA52232A (fr) | 2021-02-17 |
| EP3774805A1 (en) | 2021-02-17 |
| US11524960B2 (en) | 2022-12-13 |
| AU2019243289B2 (en) | 2023-01-12 |
| SG11202009195WA (en) | 2020-10-29 |
| EP3774805B1 (en) | 2024-01-10 |
| US20210115045A1 (en) | 2021-04-22 |
| CN111936499A (zh) | 2020-11-13 |
| NZ767697A (en) | 2025-02-28 |
| MX2020010005A (es) | 2020-10-14 |
| WO2019191470A8 (en) | 2019-12-12 |
| AR115326A1 (es) | 2020-12-23 |
| BR112020020104A2 (pt) | 2021-01-26 |
| CN111936499B (zh) | 2023-09-19 |
| CA3094476C (en) | 2025-05-06 |
| ES2973114T3 (es) | 2024-06-18 |
| CA3094476A1 (en) | 2019-10-03 |
| EA202092320A1 (ru) | 2021-03-09 |
| UA127059C2 (uk) | 2023-03-29 |
| TWI719437B (zh) | 2021-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7350005B2 (ja) | Ｍａｔ２ａの複素二環式阻害剤、およびがんの治療のための使用方法 | |
| KR102823567B1 (ko) | Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 | |
| AU2020284018A1 (en) | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | |
| KR20220050832A (ko) | Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 | |
| HK40049450A (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| HK40049450B (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| RU2809987C2 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| EA041815B1 (ru) | Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли | |
| OA20638A (en) | Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer. | |
| EA046111B1 (ru) | Гетероциклические ингибиторы mat2a и способы применения для лечения рака | |
| HK40061678A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| HK40061678B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201026 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220328 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240223 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241021 |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20241111 Comment text: Decision to Grant Registration Patent event code: PX07013S01D |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241126 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241127 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |